(+)-Bicuculline - CAS 485-49-4
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
(+)-Bicuculline
Catalog Number:
485-49-4
CAS Number:
485-49-4
Description:
(+)-Bicuculline is a competitive antagonist of GABAA receptors with IC50 of 2 μM, also blocks Ca(2+)-activated potassium channels.
Molecular Weight:
367.35
Molecular Formula:
C20H17NO6
COA:
Inquire
MSDS:
Inquire
Targets:
GABA Receptor
Chemical Structure
CAS 485-49-4 (+)-Bicuculline

Related GABA Receptor Products


CAS 53188-20-8 Etomidate Hydrochloride

Etomidate Hydrochloride
(CAS: 53188-20-8)

Etomidate hydrochloride is a GABAA receptor agonist used for the induction of general anaesthesia.

CAS 69308-37-8 (R)-baclofen

(R)-baclofen
(CAS: 69308-37-8)

(R)-baclofen a selective GABAB agonist.

CAS 21715-46-8 Etifoxine

Etifoxine
(CAS: 21715-46-8)

Etifoxine, also called as HOE 36801 or Stresam, is a positive allosteric modulator of GABAreceptors that produces anxiolytic effects by preferentially modulatin...

CAS 33125-97-2 Etomidate

Etomidate
(CAS: 33125-97-2)

Etomidate is a GABAA receptor agonist, used as a short-acting anaesthetic agent or sedative.

CAS 847353-30-4 Arbaclofen placarbil

Arbaclofen placarbil
(CAS: 847353-30-4)

Arbaclofen placarbil is a prodrug of R-baclofen. It is a GABA B receptor agonist. Arbaclofen was being developed as a potential treatment for patients with GERD...

CAS 56776-32-0 Etifoxine Hydrochloride

Etifoxine Hydrochloride
(CAS: 56776-32-0)

Etifoxine Hydrochloride is Potentiator of GABAA receptor with anxiolytic and anticonvulsant activity.

Pipequaline HCl

The hydrochloride of pipequaline. Pipequaline is a non-selective GABAA receptor partial agonist that is potentially used as an anxiolytic drug of the nonbenzodi...

CAS 155569-91-8 Emamectin Benzoate

Emamectin Benzoate
(CAS: 155569-91-8)

Emamectin Benzoate is the Emamectin derivative. Emamectin, also called as Proclaim, is widely used as an insecticide because of its chloride channel activation ...

Lorediplon
(CAS: 917393-39-6)

Lorediplon is a hypnotic drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit. It is a novel nonbenzodiazepine of the pyrazolo...

CAS 951650-22-9 NS 11394

NS 11394
(CAS: 951650-22-9)

NS 11394 is a drug with selectivity for the α3 and α5 subtypes. It acts as a subtype-selective positive allosteric modulator at GABAA receptors. It is used as a...

CAS 56287-74-2 Afloqualone

Afloqualone
(CAS: 56287-74-2)

Afloqualone is a agonist of GABA receptor has sedative and muscle-relaxant effects.

CAS 78755-81-4 Flumazenil

Flumazenil
(CAS: 78755-81-4)

Flumazenil is a GABAA receptor antagonist and the only GABAA receptor antagonist on the market today.

CAS 62666-20-0 Progabide

Progabide
(CAS: 62666-20-0)

Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...

CAS 783331-24-8 MRK 016

MRK 016
(CAS: 783331-24-8)

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid...

CAS 130477-52-0 L-655,708

L-655,708
(CAS: 130477-52-0)

L-655,708, an inverse agonist of α5 subunit involved in GABAA receptor, has been found to exhibit cognitive performance improvement in biological studies.

CAS 840486-93-3 adipiplon

adipiplon
(CAS: 840486-93-3)

Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able ...

CAS 125-33-7 Primidone

Primidone
(CAS: 125-33-7)

Primidone, a pyrimidinedione derivative, could be used as an anticonvulsant agent especially against epilepsy unspecified.

Remimazolam benzenesulfonat
(CAS: 1001415-66-2)

Remimazolam, a novel Benzodiazepine derivatives, has potential use for anxiolytic, sedative and hypnotic. For the reason that remimazolam's beding discontinued ...

TPA023
(CAS: 252977-51-8)

TPA023, also called as MK-0777, is a subtype-selective, mixed agonist-antagonist at GABAA receptor with anxiolytic and anticonvulsant effects.

CAS 207306-50-1 TB 21007

TB 21007
(CAS: 207306-50-1)

TB 21007, as a nootropic drug, is a GABAA receptor inverse agonist selective for the α5-subtype (Ki values are 1.6, 16, 20 and 20 nM for α5, α2, α1 and α3 subty...

Reference Reading


1.Delayed application of the anesthetic propofol contrasts the neurotoxic effects of kainate on rat organotypic spinal slice cultures.
Bajrektarevic D1, Nistri A2. Neurotoxicology. 2016 Mar 3;54:1-10. doi: 10.1016/j.neuro.2016.03.001. [Epub ahead of print]
Excitotoxicity due to hyperactivation of glutamate receptors is thought to underlie acute spinal injury with subsequent strong deficit in spinal network function. Devising an efficacious protocol of neuroprotection to arrest excitotoxicity might, therefore, spare a substantial number of neurons and allow later recovery. In vitro preparations of the spinal cord enable detailed measurement of spinal damage evoked by the potent glutamate analogue kainate. Any clinically-relevant neuroprotective treatment should start after the initial lesion and spare networks for at least 24h when cell damage plateaus. Using this strategy, we have observed that the gas anesthetic methoxyflurane provided strong, delayed neuroprotection. It is unclear if this beneficial effect was due to the mechanism of action by methoxyflurane, or it was the consequence of anesthetic depression. To test this hypothesis, we investigated the effect by propofol (commonly injected i.
2.TRH modulates glutamatergic synaptic inputs on CA1 neurons of the mouse hippocampus in a biphasic manner.
Zarif H1, Petit-Paitel A1, Heurteaux C1, Chabry J1, Guyon A2. Neuropharmacology. 2016 Apr 6. pii: S0028-3908(16)30140-X. doi: 10.1016/j.neuropharm.2016.04.004. [Epub ahead of print]
Thyrotropin releasing hormone (TRH) is a tripeptide that induces the release of Thyroid Stimulating Hormone (TSH) in the blood. Besides its role in the thyroid system, TRH has been shown to regulate several neuronal systems in the brain however its role in hippocampus remains controversial. Using electrophysiological recordings in acute mouse brain slices, we show that TRH depresses glutamate responses at the CA3-CA1 synapse through an action on NMDA receptors, which, as a consequence, decreases the ability of the synapse to establish a long term potentiation (LTP). TRH also induces a late increase in AMPA/kainate responses. Together, these results suggest that TRH plays an important role in the modulation of hippocampal neuronal activities, and they contribute to a better understanding of the mechanisms by which TRH impacts synaptic function underlying emotional states, learning and memory processes.
3.GABAergic signaling in the rat pineal gland.
Yu H1, Benitez SG2, Jung SR1, Farias Altamirano LE2, Kruse M1, Seo JB1, Koh DS1, Muñoz EM2, Hille B1. J Pineal Res. 2016 Mar 28. doi: 10.1111/jpi.12328. [Epub ahead of print]
Pinealocytes secrete melatonin at night in response to norepinephrine released from sympathetic nerve terminals in the pineal gland. The gland also contains many other neurotransmitters whose cellular disposition, activity, and relevance to pineal function are not understood. Here we clarify sources and demonstrate cellular actions of the neurotransmitter γ-aminobutyric acid (GABA) using Western blotting and immunohistochemistry of the gland and electrical recording from pinealocytes. GABAergic cells and nerve fibers, defined as containing GABA and the synthetic enzyme GAD67, were identified. The cells represent a subset of interstitial cells while the nerve fibers were distinct from the sympathetic innervation. The GABAA receptor subunit α1 was visualized in close proximity of both GABAergic and sympathetic nerve fibers as well as fine extensions among pinealocytes and blood vessels. The GABAB 1 receptor subunit was localized in the interstitial compartment but not in pinealocytes.
4.CB1 cannabinoid receptor-mediated anandamide signalling reduces the defensive behaviour evoked through GABAA receptor blockade in the dorsomedial division of the ventromedial hypothalamus.
Dos Anjos-Garcia T1, Ullah F1, Falconi-Sobrinho LL1, Coimbra NC2. Neuropharmacology. 2016 Apr 7. pii: S0028-3908(16)30139-3. doi: 10.1016/j.neuropharm.2016.04.003. [Epub ahead of print]
The effects of cannabinoids in brain areas expressing cannabinoid receptors, such as hypothalamic nuclei, are not yet well known. Several studies have demonstrated the role of hypothalamic nuclei in the organisation of behavioural responses induced through innate fear and panic attacks. Panic-prone states are experimentally induced in laboratory animals through a reduction in the GABAergic activity. The aim of the present study was to examine panic-like elaborated defensive behaviour evoked through GABAA receptor blockade with bicuculline (BIC) in the dorsomedial division of the ventromedial hypothalamus (VMHdm). We also aimed to characterise the involvement of endocannabinoids and the CB1 cannabinoid receptor in the modulation of elaborated defence behavioural responses organised through the VMHdm. The guide-cannula was stereotaxicaly implanted in VMHdm and the animals were treated with anandamide (AEA) at different doses, and the effective dose was used after the pre-treatment with the CB1 receptor antagonist AM251, followed by GABAA receptor blockade in VMHdm.